{
    "pmid": "41417345",
    "title": "Evaluation of T-NGS, Xpert Ultra, and Line Probe Assay on Clinical Samples for the Diagnosis of Drug-Resistant Pulmonary Tuberculosis in Rio de Janeiro.",
    "abstract": "The rapid detection of drug resistance in Mycobacterium tuberculosis is essential for managing drug-resistant tuberculosis (DR-TB). This study evaluated the performance of molecular assays compared to phenotypic drug susceptibility testing (pDST) and targeted next-generation sequencing (T-NGS). We retrospectively analyzed 40 presumptive pulmonary DR-TB cases in Rio de Janeiro from 2018 to 2022. Xpert MTB/RIF Ultra (Xpert Ultra) and Line Probe Assay (LPA; MTBDRplus = LPA-1, MTBDRsl = LPA-2) were performed directly on clinical respiratory specimens, with pDST serving as the reference standard. T-NGS was used to identify resistance mutations and clarify discordant results. Most samples (92.5%) were smear-positive. Xpert Ultra and LPA-1 demonstrated high sensitivity for detecting resistance to rifampicin (91.7% and 89.3%, respectively). However, LPA-1 exhibited lower sensitivity for isoniazid (81.5%). The performance of LPA-1 decreased in samples with cycle threshold (Ct) values â‰¥16, indicating low bacterial load (p = 0.001). T-NGS detected resistance to fluoroquinolones (22.5%) and injectables (15-20%) that was missed by LPA-2 and MGIT. Mixed infections were identified in 17.5% of samples and accounted for 27.8% of discordant results. Isoniazid heteroresistance was detected in 32.5% of samples by LPA-1 and in 7.5% by T-NGS. Xpert Ultra and LPA-1 are effective for the rapid detection of rifampicin resistance but have limitations for isoniazid and second-line drugs. T-NGS improved the detection of low-level resistance, heteroresistance, and mixed infections, supporting its implementation in reference laboratories for comprehensive DR-TB diagnosis.",
    "disease": "tuberculosis",
    "clean_text": "evaluation of t ngs xpert ultra and line probe assay on clinical samples for the diagnosis of drug resistant pulmonary tuberculosis in rio de janeiro the rapid detection of drug resistance in mycobacterium tuberculosis is essential for managing drug resistant tuberculosis dr tb this study evaluated the performance of molecular assays compared to phenotypic drug susceptibility testing pdst and targeted next generation sequencing t ngs we retrospectively analyzed presumptive pulmonary dr tb cases in rio de janeiro from to xpert mtb rif ultra xpert ultra and line probe assay lpa mtbdrplus lpa mtbdrsl lpa were performed directly on clinical respiratory specimens with pdst serving as the reference standard t ngs was used to identify resistance mutations and clarify discordant results most samples were smear positive xpert ultra and lpa demonstrated high sensitivity for detecting resistance to rifampicin and respectively however lpa exhibited lower sensitivity for isoniazid the performance of lpa decreased in samples with cycle threshold ct values indicating low bacterial load p t ngs detected resistance to fluoroquinolones and injectables that was missed by lpa and mgit mixed infections were identified in of samples and accounted for of discordant results isoniazid heteroresistance was detected in of samples by lpa and in by t ngs xpert ultra and lpa are effective for the rapid detection of rifampicin resistance but have limitations for isoniazid and second line drugs t ngs improved the detection of low level resistance heteroresistance and mixed infections supporting its implementation in reference laboratories for comprehensive dr tb diagnosis"
}